Safety
Cancer
ADVERSE EVENT, ADVERSE EVENTS, EVENT, ADVERSE EVENT, EVENTS, CANCER
Forty-eight of 49 (98%) patients were treated with one dose of DNX-2401 after a standard biopsy, which was then followed by pembrolizumab starting 7 days later. One patient enrolled in the first dose cohort received 5 × 10An overview of adverse events (AEs) in the study is summarized in Extended Data Tables AEs that were considered to be related to treatment are summarized in Table Summary of AEs related to treatmentAE denotes adverse event. SAE denotes serious adverse event. Shown are AEs and SAEs with greater than 5% frequency. Overall frequency refers to patients reporting at least one treatment related AE. Each patient is included once using the highest-grade event. Events were graded according to National Cancer Institute-Common Terminology Criteria for Adverse Events, version 4.03.